Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Gulf War Illness (GWI) are debilitating diseases with overlapping symptomology and there are currently no validated tests for definitive diagnosis of either syndrome. While there is evidence supporting the premise that some herpesviruses may act as possible triggers of ME/CFS, the involvement of herpesviruses in the pathophysiology of GWI has not been studied in spite of a higher prevalence of ME/CFS in these patients. We have previously demonstrated that the deoxyuridine triphosphate nucleotidohydrolases (dUTPase) encoded by Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6), and varicella-zoster virus (VZV) possess novel functions in innate and adaptive immunity. The results of this study demonstrate that a significant percentage of patients with ME/CFS (30.91-52.7%) and GWI (29.34%) are simultaneously producing antibodies against multiple human herpesviruses-encoded dUTPases and/or the human dUTPase when compared to controls (17.21%). GWI patients exhibited significantly higher levels of antibodies to the HHV-6 and human dUTPases than controls (P = 0.0053 and P = 0.0036, respectively), while the ME/ CFS cohort had higher anti-EBV-dUTPase antibodies than in both GWI patients (P = 0.0008) and controls (P < 0.0001) as well as significantly higher anti-human dUTPase antibodies than in controls (P = 0.0241). These results suggest that screening of patients' sera for the presence of various combinations of anti-dUTPase antibodies could be used as potential biomarkers to help identify/distinguish patients with these syndromes and better direct treatment.
and debilitating symptoms including fatigue, musculoskeletal pain, and cognitive problems, GWI has no known cure and requires long-term treatment and monitoring. 9 Multiple hypotheses regarding the etiology of these symptoms soon emerged, as these servicemen were subjected to a number of potentially hazardous conditions, including infectious agents, medical prophylaxis, pesticides, depleted uranium, oil well fire smoke, chemical, and biological warfare agents and psychological stressors. 10 GWI cases exhibit a significant overlap in symptoms with ME/CFS, which include long-term fatigue, sleep disturbances or non-restorative sleep, as well as immune and cognitive dysfunction. [11] [12] [13] There are currently no validated biomarkers for definitive diagnosis of either syndrome. Thus, there is an urgent need to identify triggers and drivers of ME/CFS and GWI and to understand the molecular mechanisms by which they contribute to the development or progression of these illnesses so more efficient diagnostic tools and effective therapeutics can be developed.
We have previously demonstrated that the deoxyuridine triphosphate nucleotidohydrolase (dUTPase) encoded by EBV, HHV-6, and VZV possess novel immunoregulatory functions by triggering the activation of toll-like receptor (TLR) 2, which leads to the activation of NF-κB and subsequent modulation of downstream genes involved in chronic inflammation, effector T-cell function and neurotransmitter function. [14] [15] [16] [17] We have also shown that the EBV-encoded dUTPase is secreted in exosomes, which function as intracellular messengers, induces the secretion of the pro-inflammatory T H 1/T H 17 cytokines, alters T-and NK cell function in vitro, and induces anxiety and sickness behavior in mice. 18, 19 Perhaps more importantly, was the finding of prolonged and significantly elevated neutralizing antibodies against the EBV-encoded dUTPase, which inversely correlated with ME/CFS symptomology in a small subset of patients with ME/CFS. 20 In this study, we examined, using a newly developed ELISA assay, longitudinal samples from a cohort of patients with ME/CFS enrolled in the "Good Day Bad Day" study and single serum samples from other cohorts of patients diagnosed with GWI or ME/CFS as well as gender, age, and ethnicity matched controls. The samples were examined for the presence of IgG antibodies against the HHV-6, EBV, and VZV encoded dUTPases as well as the human nuclear dUTPase. The ELISA assay is more advantageous than the previously employed neutralization assays in that it is more rapid, allows for the detection of a wide assortment of antibodies directed against the proteins rather than just those that neutralize enzymatic activity. This is important in the case of dUTPases such as HHV-6, which lack functional enzymatic activity. 17 Altogether, our data is consistent with previous findings supporting aberrant immune responses and a loss in immune competence in ME/CFS and GWI patients. This could result in lytic/abortive replication of these herpesviruses and subsequent expression of virus-encoded dUTPases, which in turn may contribute to the immunopotentiation of the disease process.
| MATERIALS AND METHODS

| Purification of recombinant dUTPase proteins
Subcloning and purification of the recombinant herpesviruses' dUTPase proteins (HHV-6, EBV, and VZV), as well as, the human nuclear dUTPase were performed as we have described previously. [14] [15] [16] [17] While the HHV-6A U45 gene was cloned from the HHV-6A strain GS, the recombinant protein exhibits greater than 94% identity to the HHV-6B strain Z29 U45 gene. Therefore, it is unlikely that the U45 recombinant protein can distinguish between these strains. The terminology HHV-6 will be employed. All recombinant dUTPase protein preparations were tested for the presence of contaminants as described previously [14] [15] [16] [17] and were free of detectable levels of LPS, peptidoglycan (SLP-HS), DNA, or RNA.
Protein concentration was determined using the Qubit fluorimeter (Invitrogen Carlsbad, CA). The purified recombinant dUTPase proteins used in these studies were stored at −80°C until further use.
| ELISA assay
ELISAs were performed essentially as described previously. were subtracted from the mean absorbance of the coated wells.
ROC curves were constructed to determine optimal threshold points for each antigen using serum obtained from a healthy control donor.
Intra-assay variation was determined to be less than 0.02 while inter-assay variation ranged from 0.005 for human to 0.049 for VZV. The recombinant dUTPase-specific ELISAs were validated using dUTPase-specific antibodies to the EBV, HHV-6 dUTPases, and the human nuclear dUTPase and no cross-reactivity was observed.
Because of the low protein homology among the herpesviruses' dUTPases (maximum amino acid identity between EBV dUTPase, HHV-6 dUTPase, and VZV dUTPase is 24%), it is very unlikely that these dUTPases will bind to each other. 
| ME/CFS exclusion criteria
Following the recommendations of Reeves et al, 24 all ME/CFS subjects, selected by their medical history and physical examination, had no history of heart disease, COPD, malignancy, or other systemic disorders including the listed psychiatric exclusions that would be exclusionary for a diagnosis of ME/CFS.
Patients taking medications that have the potential to act as significant immunomodulators were excluded including gamma globulin, steroids, and any cytokine or cytokine-blocking therapy.
Medications with modest immunologic impact (eg, anti-depressants)
were maintained without change in dosage throughout the study periods.
| ME/CFS longitudinal good day bad day study subjects
In 74 subjects with ME/CFS, baseline and 18 month blood samples and clinical data were collected. Two additional blood samples were collected from each subject, one on a day the subject self-described feeling "relatively good" and another one when the subject was having "bad day" (Table 1 ). There was a minimum of a 3-month period between the collection of sera from a good day and a bad day.
| ME/CFS single sample study subjects
A single baseline serum sample from 55 ME/CFS subjects in our biobank was selected for testing. There was no overlap between these single sample ME/CFS patients and those in the ME/CFS Good Day Bad Day group. Demographic details of these patients are given in Table 1 .
| Gulf war illness cohort
Inclusion criteria for GWI was derived from Fukuda et al, 8 and consisted in identifying veterans deployed to the theater of operations between August 8, 1990 and July 31, 1991, with one or more symptoms present after 6 months from at least two of the following: fatigue; mood and cognitive complaints; and musculoskeletal complaints. Subjects were in good health prior to 1990 and had no current exclusionary diagnoses. Medications that could have impacted immune function were excluded as were supplements. The use of the Fukuda definition in GWI is supported by Collins et al. 25 A single baseline serum sample from 45 GWI subjects in our biobank was selected for this study.
Demographic details of these patients are given in Table 1 .
Healthy controls were self-defined as healthy, sedentary (no regular exercise program, sedentary employment), and matched to ME/CFS or GWI cases by age (±5 years), gender, and race/ethnicity (see Table 1 ).
| Herpesvirus serology
The average age of the subjects in this study ranged from 44.09 to 49.5 years and since 70-95% of the adult population has been infected with EBV, HHV-6, and VZV, standard herpesviruses serological assays were not performed.
| Statistical analysis
GraphPad Prism 6 software (GraphPad Software, La Jolla, CA) was used for all statistical analyses. For the longitudinal ME/CFS GDBD samples, Pearson's correlation coefficient was determined. A P-value of <0.05 was used to demonstrate a significant correlation between the expression of the various antibodies within the groups examined.
For the GWI study, while only one serum sample was available per patient, the means of the various groups cross-sectional were compared using one-way analysis of variance (ANOVA). Values of P < 0.05 were considered statistically significant. To compare two groups an unpaired t-test was employed. Values of P < 0.05 were considered statistically significant.
3 | RESULTS
| Evaluation of humoral immune responses to herpesviruses and human dUTPase proteins in ME/CFS good day bad day longitudinal sera
To determine whether there was evidence supporting the hypothesis that herpesviruses-dUTPase proteins were expressed in patients with ME/CFS, we tested longitudinal sera from 74 ME/CFS Good Day-Bad Day (GDBD) patients (Table 1) , for antibody responses against EBV, HHV-6, and human nuclear encoded dUTPases by ELISA.
As shown in Table 2 , a spectrum of humoral reactivities to the various dUTPases was observed in the ME/CFS GDBD cohort. Of the 74 patients examined, approximately 34% were negative for antibodies to HHV-6, EBV-, and the human nuclear encoded dUTPase proteins. While some patients expressed antibodies to only HHV-6 (2.7%) or EBV (5.41%) encoded dUTPases, the majority (48.65%) coexpressed antibodies to both HHV-6 and EBV-encoded dUTPases (Table 2) . Furthermore, 55.40% and 54.06% of the total ME/CFS GDBD cohort were positive (single or double) for HHV-6 and EBV antidUTPase antibodies, respectively. While a few patients were positive only for anti-human dUTPase antibodies (6.76%), somewhat surprising was the observation that a significant proportion of the ME/CFS GDBG cohort co-expressed anti-human and anti-HHV-dUTPase antibodies (31.08%) ( Table 2 ).
There was no direct correlation between the levels of antidUTPase antibodies and patients' self-determination of whether they were having a good day or a bad day. Twenty-four patients, who were negative for anti-dUTPase antibodies, exhibited no significant change in antibody levels during the test period ( Fig. 1E patient 055) , while seven patients (14%) exhibited the highest level of antibodies at the conclusion of the test period.
Twenty-seven patients (54%) exhibited a peak of anti-dUTPase antibody either on the bad day or on the good day and this was followed by an increase of antibodies at the end of the trial (Fig. 1F-H 3.2 | Antibody responses to herpesviruses and human nuclear dUTPase proteins in GWI, ME/CFS, and healthy control sera
Because of the overlapping symptoms observed between patients with GWI and ME/CFS, 26,27 the higher incidence of ME/CFS in patients with GWI and the lack of information concerning the etiology of GWI, we next examined the potential involvement of herpesviruses in the pathophysiology of GWI. To determine whether there was evidence supporting the hypothesis that herpesvirusesdUTPase proteins were expressed in patients with GWI, the antidUTPase antibody profile to HHV-6, EBV, and VZV encoded dUTPases as well as the human dUTPase were determined in a single serum sample from 58 patients diagnosed with GWI and compared to the antibody profiles obtained in patients diagnosed with ME/CFS (n = 55) or healthy controls (n = 151). As shown in Table 3 , a wide-spectrum of anti-dUTPase antibodies were identified in patients (GWI; ME/CFS).
As shown in Fig. 2 , there were statistically significant differences in the expression of anti-dUTPase antibodies between the GWI, ME/ CFS, and control cohorts based upon unpaired t-test analyses. The GWI cohort exhibited a statistically significant increase in anti-HHV-6
(P = 0.0053; Fig. 2A ), anti-VZV (P = 0.032; Fig. 2B ), and anti-human (P = 0.0036; Fig. 3C ) dUTPase antibodies when compared to controls while the ME/CFS cohort exhibited a statistically significant increase in anti-EBV (P = 0.0001; Fig. 2D ) and anti-human (P = 0.0241; Fig. 2C) dUTPase antibodies when compared to controls. Interestingly, the only statistically significant difference between the GWI and ME/CFS cohorts was an elevation in anti-EBV dUTPase antibodies in the ME/ CFS cohort (P = 0.0008; Fig. 2D ) and an elevation of anti-VZV dUTPase antibodies in the GWI cohort (P = 0.0441; Fig. 2B ).
Collectively, these results demonstrate a significant increase in IgG antibodies to EBV, HHV-6, VZV, and human nuclear dUTPases suggesting that certain epitopes in the herpesviruses and human nuclear dUTPase proteins may be eliciting an immunological response in some patients with ME/CFS and/or GWI.
| DISCUSSION
ME/CFS and GWI are chronic multisystem illnesses with overlapping symptoms including fatigue, neurocognitive dysfunctions, and immune activation (elevation of inflammatory markers and elevated cytokine levels). This is further complicated by the fact that GWI patients have an increased prevalence of chronic fatigue compared to the general population. 26, 27 Furthermore, there are currently no biomarkers available that are clinically useful for differential diagnoses.
Attempts to identify the etiological agents/triggers responsible for these multisystem illnesses have not been successful. Likewise, while numerous studies have demonstrated immune dysfunction in these patients including alterations in cytokine patterns and decreased NK cell function, the factors that act as drivers, which power and maintain these multisystem illnesses are unknown.
Our study demonstrates that a subgroup of patients diagnosed with either ME/CFS or GWI exhibited a statistically significant elevation in antibodies against the HHV-6, EBV, and VZV encoded dUTPases, proteins that are only expressed during lytic or abortive lytic replication of these viruses, as well as the human nuclear dUTPase. These results suggest that in this subgroup of patients there is reactivation of multiple herpesviruses; a feature that is also observed in some transplant recipients 28, 29 and patients with drug-induced hypersensitivity syndrome (DISS/DRESS). [30] [31] [32] Since GWI patients were exposed to a variety of chemical agents and environmental toxins a DIHS/DRESS-like reaction could contribute to the reactivation of herpesviruses, especially HHV-6 in these patients. While the mechanism(s) responsible for the simultaneous reactivation of these herpesviruses is unknown, it suggests a loss of immunological control primarily, at the CD8 + T-cell level. This is supported in part by a study demonstrating deficient EBV-specific T-cell responses in some ME/ CFS patients. 7 Our study demonstrates for the first time, the presence of autoantibodies against the human dUTPase in a subgroup of patients with ME/CFS and GWI. In our study 39.10% of the patients in the GDBD cohort, 14.55% and 18.6% of the ME/CFS and GWI patients, respectively, possessed antibodies either alone or in combination with the anti-herpesviruses' dUTPases when compared to the controls (4.64%). It is unlikely that the observed humoral response to the human dUTPase is due to cross-reactivity with the herpesvirusesencoded dUTPases since there is little homology between the homotrimeric human dUTPase and the monomeric herpesviruses dUTPases. Further antibody characterization studies using polyclonal antibodies against the EBV-encoded dUTPase revealed no reaction with the human dUTPase (data not shown). The human nuclear dUTPase, which is released from B cells in exosomes, 33 was identified as an autoantigen and potential biomarker for autoimmune hepatitis. 34 Previous studies have demonstrated the presence of autoantibodies in patients with ME/CFS and in Gulf War veterans against numerous cellular components including nuclear envelope, 35 muscarinic Repetitive longitudinal serum samples (n = 4 samples/patient and a total of 74 patients) were examined for anti-HHV-6, EBV, and human dUTPase antibodies by ELISA as described in Materials and Methods. Data represent the average of n ≥ 4 measurements/sample for each recombinant protein at each time point (baseline, good day, bad day, end). A positive reaction was defined as a serum sample that led to a signal three-times over the background OD of the control serum. A patient was considered positive for Abs to a specific dUTPase if a positive reaction occurred at any time point.
cholinergic and β-adrenergic receptors 36,37 anchorage molecules, 38 DNA, 39 myelin basic protein and smooth, and striated muscle tissue. 40 While additional studies are needed to determine the role, if any, of these autoantibodies in the disease process, our study suggest that antibodies against human, EBV, HHV-6, and VZV dUTPases may be useful as biomarkers to differentiate between patients with ME/CFS and GWI.
Numerous studies have suggested a potential role for HHV-6
and/or EBV as triggers for ME/CFS 3,5-7 and limited studies have suggested the involvement of VZV in ME/CFS. 41, 42 Conversely, there has only been a single study on GWI patients and herpesviruses suggesting that there was reactivation of multiple herpesviruses (HHV-6, EBV, and VZV) in these patients. 40 Our studies on ME/CFS are unique in that they focused on determining whether there was an increase in antibodies against a class of dUTPase proteins that have been shown to regulate immune and neurocognitive functions and thus, have the ability/potential to drive/exacerbate the pathophysiological alterations that occur in the course of ME/CFS. Furthermore, we wanted to determine whether a similar antibody profile is observed in patients with GWI, who have a higher prevalence of ME/CFS and who exhibit similar symptomology. The data from this study support the hypothesis that in some patients with ME/CFS and/or GWI there is a complex interaction between various herpesviruses resulting in Grouping of GWI and ME/CFS patients based upon anti-HHV-6, EBV, VZV, and Human dUTPase antibodies a dUTPase Ab subgroup GWI cohort; N (% of total) ME/CFS cohort; N (% of total) Control cohort; N (% of total) 
44-48
Similar studies have not been performed with GWI patients, although long-term valcyclovir treatment of military personnel with chronic pain associated with atypical herpesvirus reactivation improved symptoms. 49 In summary, we have shown that some ME/CFS and GWI patients exhibit a statistically significant increase in IgG antibodies to EBV, HHV-6, VZV, and human nuclear dUTPases relative to controls suggesting that the dUTPases encoded by these herpesviruses are expressed at sufficient quantities in these patients to trigger a humoral immune response. This study provides further evidence that the herpesviruses-encoded dUTPases may be involved in the pathophysiology in a subset of patients with ME/CFS and GWI. The data from this study also support the hypothesis that in some patients with ME/CFS and/or GWI there is a complex interaction between various herpesviruses resulting in increased expression of the virus-encoded dUTPases and warrants further studies to address whether the presence of various combinations of antibodies to the herpesviruses encoded dUTPases could be used as potential biomarkers with clinical application for directing the use of specific long-term antiviral chemotherapy.
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FIG . 3 Proposed mechanism(s) by which HHV-6, EBV, and VZV reactivation can drive ME/CFS and GWI symptomology. Abortive/ lytic reactivation of HHV-6, EBV, and/or VZV results in the expression of the early gene product dUTPase and subsequent release either through pyroptosis (localized effect) or in exosomes (systemic effect). Binding of virus dUTPase to TLR2 on target cells (DCs, PBMCs, NK, T-cells) leads to NF-κB activation, followed by induction/secretion of pro-inflammatory cytokines and the up-regulation of genes involved in inflammation, T H 17 differentiation, modulation of neurotransmitters, and genes involved with brain function
